- A Better Drug Than Merck’s Blockbuster Keytruda? Not So Fast The Wall Street Journal
- With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights STAT
- Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial Barron’s
- Akeso, Summit’s PD-1 bispecific crushes…
[ad_2]
Source link